Key Points Alto Neuroscience (NYSE:ANRO) reported a net loss of $17.7 million (GAAP) in Q2 2025, with EPS of $(0.65) (GAAP). No revenue was reported, as the company remains in the clinical-stage ...

Net loss (GAAP) widened year over year for the six months ended Q2 2025, driven by sharply higher research and administrative expenses. Revenue (GAAP) fell 31.0% year-over-year for the six months ...

A study in JDR Clinical & Translational Research demonstrates that arginine dentifrices reduce dental caries in children with ...

Initiates Critical Milestone, Launching Phase 3 Trial of PF614 to Advance Next-Generation Opioid Therapy Toward Regulatory ApprovalReceives $5.3 Million Installment from NIDA To Support Overdose Prote ...

Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data support potential for meaningful ...

Compelling new ARD-201 preclinical data informs optimized Phase 2 clinical development strategy of obesity programs: Phase 2 POWER trial of oral ARD-201 to focus on weight rebound in patients ...

NRG Oncology recently reported the results of the phase II/III NRG-BN007 clinical trial showing that combining ipilimumab and ...

Shore Capital Partners has formed PhaseWell Research, a Nashville-based clinical research site company. No financial terms were disclosed. In conjunction with the formation, Carsten Bick has been ...

People with multiple sclerosis tend to have frequent doctor's appointments up to 15 years before diagnosis, recent research ...

Discover BiomX's Q2 2025 updates, including progress in phage therapy trials BX004 & BX211, financial highlights, and key insights into upcoming ...

Discover PDS Biotechnology's Q2 2025 progress on groundbreaking cancer trials, including VERSATILE-003. Explore durable outcomes and market growth potential.

Denifanstat met all primary and secondary endpoints in Phase 3 clinical trial in moderate to severe acne conducted by license ...